The new version of the drug catalog affects the nerves of investors. Which pharmaceutical products have been shortlisted?

[pharmaceutical network industry trends 】Recently, 148 new varieties have been added to the regular access section of the new version of the medical insurance drug catalog, covering the priority national essential drugs, cancer and rare diseases and other major disease treatment drugs, chronic disease drugs, children's drugs, first-aid and rescue drugs, including the famous anti-cancer drugs such as rituximab, imatinib and exetinib The new medical insurance drug catalog affects the nerves of major drug companies and investors Up to now, many listed pharmaceutical companies have disclosed the quick report that their products are included in the national medical insurance drug catalog According to incomplete statistics, the author combs the inclusion and adjustment of 14 enterprises that have products shortlisted East China Pharmaceutical Co., Ltd announced Monday that one of its wholly-owned subsidiaries, Sino US East China and Xi'an Bohua, was newly included in the drug catalog, and the products originally included in the 2017 version of the drug catalog will continue to be included in the drug catalog this time In addition, a number of varieties currently in the R & D stage of the company are also included in the drug catalog, which will have a positive impact on the promotion of the company's innovation, transformation and development strategy and the marketing after successful R & D in the future Zhongsheng Pharmaceutical Co., Ltd has 249 selected products, including 147 in class A and 102 in class B The core products, such as compound Xueshuantong capsule, Naoshuantong capsule, and potential product sucralfate oral suspension, are all included in the drug catalog 2019 At the same time, the company said that the selected products may face the risk of price adjustment The specific sales situation of drugs in the future may be affected by market environment changes and other factors The impact on the company's business performance cannot be estimated temporarily, and will not have a significant impact on the company's performance in the short term Lizhu group and its subsidiaries have 186 products in total, including 95 in class A and 91 in class B At the same time, the company's products transferred out of the national drug catalog by Lizhu group totaled 21, 18 of which have been stopped production and sale, and the products in production and sale withdrawn from Lizhu group do not have a significant impact on the company's operation The company said that most of the company's key products, especially individual products, will be included in the new version of the "medical insurance catalog", which will obtain the active procurement and clinical application of medical institutions, be conducive to promoting the market promotion of these products, and will have a positive impact on the company's business performance in the long run Yiling pharmaceutical Yiling Pharmaceutical Co., Ltd was selected into 7 drugs this time, including Tongxinluo tablet (capsule), Shensong Yangxin capsule, Lianhua Qingwen tablet (capsule, granule) and Qiliqiangxin capsule The company said that the inclusion of its products into the new version of the national health insurance catalogue is conducive to its marketing However, the impact on the company's operating performance cannot be estimated temporarily, and will not have a significant impact on the company's performance in the short term Beida Pharmaceutical Co., Ltd the product that Beida Pharmaceutical Co., Ltd included in the "drug catalog" this time, exetinib, belongs to the category B of medical insurance, and is a targeted drug for lung cancer treatment with independent intellectual property rights in China According to the performance forecast in the first half of the year, sales volume of ektini continued to increase by 31.26% year-on-year, and net profit increased by 20% - 40% year-on-year However, in the face of market pressure brought by centralized procurement with volume, the company said in the announcement that the impact on the company's operating performance could not be estimated temporarily Panlong seven tablets of Panlong pharmaceutical are included in Category A of the drug catalogue According to the company, Panlongqi tablet is a product of the company, which is composed of 29 kinds of Chinese herbal medicines Among them, Panlongqi, zhuangjindan, guoshanlong, zhuzishen and other 13 kinds of rare and genuine herbal medicines are all unique natural and precious Chinese herbal medicines growing at an altitude of more than 1800 meters in Qinba mountain area The company said that the inclusion of the seven Panlong tablets into the category a scope of the national drug catalog is conducive to the expansion of the company's product market layout and market share, and has a positive effect on the company's long-term development Children's Antipyretic Oral Liquid of Tailong Pharmaceutical Co., Ltd has been incorporated into the drug catalogue In addition, the medical insurance category of Shuanghuanglian oral liquid of the company has been adjusted from category B to category A; 892 varieties of traditional Chinese medicine that are paid by the fund have been specified in the catalogue of traditional Chinese medicine pieces, and the varieties of traditional Chinese medicine pieces that are not allowed to be paid by the fund have been adjusted It is worth mentioning that the products newly included in the national health insurance catalog are not the company's varieties, nor the company's current main products A total of 30 varieties of Xianju pharmaceutical have entered the drug catalog, including 10 in class A and 20 in class B The two varieties of Mometasone Furoate Gel and Fluticasone Propionate Cream belong to the new entry varieties, and the impact on the company's future business performance can not be accurately predicted at any time, and will not have a significant impact on the company's performance in the short term Zhongheng group and Zhongheng group's products included in the catalogue of drugs for injection Xueshuantong (freeze dry) and Xueshuantong injection are all class a medical insurance In addition, the reimbursement scope of this medical insurance catalog subtracts two indications of Xueshuantong for injection (freeze-dried) and Xueshuantong injection products: blood stasis and collaterals blocking, chest arthralgia and heartache According to the company, the medical insurance catalogue will be officially implemented on January 1, 2020 According to the analysis of the company's sales data in 2018, the sales volume of Xueshuantong is expected to decrease by 15% - 25% in 2020 Qianjin Pharmaceutical Co., Ltd among the drugs listed in the national medical insurance catalog this time, 2 drugs were selected, 5 drugs were adjusted according to the medical insurance classification, and 1 drug was withdrawn from the medical insurance catalog Liuwei Anshen capsule, a pharmaceutical product of Huasen pharmaceutical, was selected into the category B scope of the national medical insurance catalogue Huasen pharmaceutical said that Liuwei Anshen capsule is an important product of the mental nervous system, one of the three major advantages of the company This time, Liuwei Anshen capsule was selected into the category B scope of the national medical insurance catalog, which is expected to expand the market share of the product Gatifloxacin Eye Gel, a product of Xingqi eye drops and eye drops, has been incorporated into the national health insurance catalogue In addition, Deproteinized Calfblood Extract Eye Gel of the company withdrew from the national health insurance directory The company said that the impact of the company's products newly incorporated into and withdrawn from the national health insurance catalog on the company's business performance could not be estimated temporarily, and would not have a significant impact on the company's performance in the short term Xuesaitong dispersible tablet, one of Fangsheng pharmaceutical's main products, has entered the 2019 medical insurance catalog Other major products of the company and its holding subsidiaries have not withdrawn from the 2019 medical insurance catalog, which will have a positive effect on future sales and long-term development, but will not have a significant impact on short-term business performance There are 28 drugs in production in Wuzhong, Jiangsu Province, which have entered the national medical insurance catalogue Among them, there is one new drug in production this time, and two drugs out of production Abidol hydrochloride tablets are newly included in the national medical insurance catalogue, and ribavirin injection and vinpocetine injection are withdrawn from the national medical insurance catalogue As the above varieties are not the company's core varieties, the withdrawal from the national medical insurance catalog has no significant impact on the company's performance.